NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 1 of 37  
 
 
 
 
 
 
 
 
 
Clinical Investigational Plan  
 
 
Study Title : A Multicenter, Prospective, Treat and Resect  IDE Feasibility Study of the 
CellFX® System for the Treatment of Basal Cell Carcinoma  (BCC) Lesions  
 
 
 
Short Title: CellFX  Treat & Resect  BCC Feasibility Study  
 
 Protocol No: NP -TR-014 
Version 2.0 
29-APR-2021 
 
 
IDE Number: G210100   
NCT: [ZIP_CODE] 381 
 
 
Study  Sponsor:  
 
Pulse Biosciences, Inc.  
[ADDRESS_1020312], CA [ZIP_CODE]  
 
 
This document is a confidential communication of Pulse Biosciences, Inc.  The recipi[INVESTIGATOR_648942], Inc. except that this do cument 
may be disclosed to appropriate institutional review  boards, ethics committees or duly authorized representatives of the U.S. Food 
and Drug Administration or other responsible regulatory authorities under the condition that confidentiality is maintained.  
 
PROPRIETARY AND CONFIDENTIAL  
 
 
 
  

NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 2 of 37  
TABLE OF CONTENTS  
 
STUDY CONTACTS  ................................ ................................ ................................ ..............................  4 
1.0 INTRODUCTION AND BACKGROUND  ................................ ................................ ................  5 
1.1 Basal Cell Carcinoma Lesions  ................................ ................................ ...............................  5 
1.2 Current Care  ................................ ................................ ................................ ..........................  5 
1.3 Non-Surgical Approach  ................................ ................................ ................................ ..........  5 
1.4 Surgical Approach  ................................ ................................ ................................ ..................  7 
1.5 Alternative Approach  ................................ ................................ ................................ ..............  8 
1.6 Study Rationale  ................................ ................................ ................................ ......................  8 
2.0 STUDY DEVICE DESCRIPTION  ................................ ................................ ...........................  9 
2.1 Pulse Bioscience CellFX® System  ................................ ................................ .........................  [ADDRESS_1020313] Selection  ................................ ................................ ................................ .................  13 
4.2.1  Inclusion Criteria  ................................ ................................ ................................ ..................  13 
4.2.2  Exclusion Criteria  ................................ ................................ ................................ .................  14 
4.3 Process for Obtaining Informed Consent  ................................ ................................ .............  14 
4.3.1  Process for Obtaining Informed Consent  ................................ ................................ .............  15 
4.3.2  Addition of New Information  ................................ ................................ ................................ . 15 
4.4 Schedule of Events and Evaluations  ................................ ................................ ...................  16 
4.5 Screening / Enrollment Procedures (Visit 1)  ................................ ................................ ........  17 
4.5.1  Activities prior to or on same day as study enrollment  ................................ ........................  17 
4.5.2  Definition of Enrollment  ................................ ................................ ................................ ........  17 
4.5.3  CellFX Treatment Procedure  ................................ ................................ ...............................  17 
4.6 3-Day Follow -up Visit (Visit 2)  ................................ ................................ ..............................  18 
4.7 7-Day Follow -up Visit (Visit 3)  ................................ ................................ ..............................  18 
4.8 14-Day Follow -up Visit (Visit 4)  ................................ ................................ ............................  18 
4.9 30-Day Follow -up Visit (Visit 5)  ................................ ................................ ............................  18 
4.10  60-Day Follow -up Visit (B CC Surgical Excision Day – Visit 6)  ................................ ............  [ADDRESS_1020314] -Excision Follow -up Visit (Visit 7)  ................................ ................................ ..... [ADDRESS_1020315] -Excision Follow -up Visit (Visit 8)  ................................ ................................ ..... [ADDRESS_1020316] -Excision Follow -up Visit (Visit 9)  ................................ ................................ ..... [ADDRESS_1020317] to Follo w-Up ................................ ................................ ................................ .................  20 
5.0 BENEFITS AND RISKS  ................................ ................................ ................................ ....... 20 
5.1 Benefits  ................................ ................................ ................................ ................................  20 
5.2 Risks  ................................ ................................ ................................ ................................ .... 21 
5.3 Mitigation of Risks  ................................ ................................ ................................ ................  21 
6.0 STATISTICAL CONSIDERATIONS  ................................ ................................ .....................  22 
6.1 General Approach  ................................ ................................ ................................ ................  22 
6.2 Analysis of the Primary Effectiveness Endpoint  ................................ ................................ .. 22 
6.3 Analysis of Secondary Endpoints  ................................ ................................ ........................  22 
6.3.1  Change in Lesion Size  ................................ ................................ ................................ .........  22 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 3 of 37  
6.3.2  Lesion Reduction Category ................................ ................................ ................................ .. 22 
6.3.3  Partial response of target (study) lesion as assessed by [CONTACT_746077]  .............................  23 
6.3.4  SCAR -Q Appearance Scale (Subject)  ................................ ................................ .................  23 
6.3.5  Manchester Scar Scale (Investigator)  ................................ ................................ ..................  23 
6.3.6  Healing assessment questions (Investigator)  ................................ ................................ ...... 23 
6.4 Safety Endpoints  ................................ ................................ ................................ ..................  24 
6.4.1  Primary Safety Endpoint  ................................ ................................ ................................ ...... 24 
6.4.2  Investigator Local Skin Reaction Assessment  ................................ ................................ ..... 24 
6.4.3  Participant Assessment of Procedural Pain ................................ ................................ .........  24 
6.5 Sample Size Determination  ................................ ................................ ................................ . 25 
6.6 Populations for Analyses  ................................ ................................ ................................ ..... 25 
6.7 Sub-Group Analyses  ................................ ................................ ................................ ............  25 
6.8 Interim Analyses  ................................ ................................ ................................ ..................  25 
6.9 Missing Data  ................................ ................................ ................................ ........................  25 
6.10  Exploratory Analysis  ................................ ................................ ................................ ............  25 
7.0 CLINICAL PHOTOGRAPHY  ................................ ................................ ................................  26 
8.0 ADVERSE EVENTS  ................................ ................................ ................................ ............  26 
8.1 Adverse Event Definitions  ................................ ................................ ................................ .... 27 
8.1.1  Adverse Event (AE): ( ISO [ZIP_CODE]:2011 3.2 )................................ ................................ .........  [ADDRESS_1020318] (ADE): ( ISO [ZIP_CODE]:2011 3.1 ) ................................ ..........................  27 
8.1.3  Serious Adverse Event (SAE) (ISO [ZIP_CODE]:2011 3.37)  ................................ ........................  [ADDRESS_1020319] (SADE): (ISO [ZIP_CODE]:2011 3.36)  ................................ ........  [ADDRESS_1020320] (UADE): (21CFR812.3)  ................................ ............  28 
8.2 Device Deficiencies ( ISO [ZIP_CODE]:2011 3.15 ) ................................ ................................ ........  28 
8.2.1  Definitions  ................................ ................................ ................................ ............................  28 
8.3 Safety Reporting Requirements  ................................ ................................ ...........................  28 
9.0 STUDY MANAGEMENT (SPONSOR RESPONSIBILITIES)  ................................ ..............  29 
9.1 Sponsor Ethical and Regulatory  Considerations ................................ ................................ .. 29 
9.2 Selection of Clinical Sites ................................ ................................ ................................ ..... 29 
9.3 Site Training  ................................ ................................ ................................ .........................  29 
9.4 Investigator Training  ................................ ................................ ................................ ............  30 
9.5 Monitoring of Study Sites  ................................ ................................ ................................ ..... 30 
9.5.1  Monitoring Methods  ................................ ................................ ................................ .............  30 
9.5.2  Periodic Monitoring Visits (Onsite and Remote)  ................................ ................................ .. 30 
9.5.3  Site Close -out Visit  ................................ ................................ ................................ ...............  31 
9.6 Protocol Deviations  ................................ ................................ ................................ ..............  31 
9.7 Study Completion  ................................ ................................ ................................ .................  31 
9.8 Audits / Ins pections  ................................ ................................ ................................ ..............  31 
9.9 Publication Policies  ................................ ................................ ................................ ..............  32 
9.10  Data Management  ................................ ................................ ................................ ...............  32 
9.11  Case Report Forms /Transmission of Data  ................................ ................................ .........  32 
9.12  Data Retention  ................................ ................................ ................................ .....................  32 
10.0  INVESTIGATOR RESPONSIBILITIES  ................................ ................................ ................  33 
10.1  IRB Approval and Informed Consent  ................................ ................................ ...................  33 
10.2  Data Collection and Reporting  ................................ ................................ .............................  33 
10.3  Source Documents / Records Retention  ................................ ................................ .............  34 
10.4  Device Accountability  ................................ ................................ ................................ ...........  34 
11.0  REFERENCES  ................................ ................................ ................................ ....................  35 
12.0  APPENDICES  ................................ ................................ ................................ ......................  35 
12.1  Appendix A: Patient Informed Consent  ................................ ................................ ................  35 
12.2  Appendix B: Case Report Forms  ................................ ................................ .........................  35 
APPENDIX A: Patient Informed Consent  ................................ ................................ ........................  36 
APPENDIX B: Case Report Forms  ................................ ................................ ................................ .. 37 
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020321], CA [ZIP_CODE]  
Phone: 919 .757.2033  
[EMAIL_8277]  
Central Institutional Review Board  Advarra Institutional Review Board  
[ADDRESS_1020322]  
Columbia, MD [ZIP_CODE] [LOCATION_003]  
Phone: [PHONE_9018]  
Dermatopathology/Core Lab  
 Darius Mehregan, M.D.  
Aurora Diagnostics  
Pi[INVESTIGATOR_746054]  
[ADDRESS_1020323]  
Monroe, Mi. [ZIP_CODE]  
Phone: [PHONE_15569]    
 
Clinical Photography  
 Canfield Scientific, Inc.  
[ADDRESS_1020324]  
Parsippany, NJ [ZIP_CODE]  
 
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 5 of 37  
1.0 INTRODUCTION AND BACKGROUND  
1.1 Basal Cell Carcinoma  Lesions  
Basal cell carcinoma (BCC) arises from the basal cell layer of the epi[INVESTIGATOR_746055] .1 The lesions usually occur on sun -exposed skin in 
adults, and locations are stratified by [CONTACT_66443].  Medium - and high -risk locations are the head, neck, 
genitals, hands, feet, and pretibial while low risk areas are the trunk and extremities (aside from 
the ankles and other areas included in the medium - and high -risk locations).2 BCC lesions are 
rarely lif e threatening and the primary goal of treatment is complete removal of the tumor with 
maximum preservation of function and cosmesis.2  
 
1.2 Current Care  
The current care of BCC lesions include s topi[INVESTIGATOR_2855] s such as  imiquimod cream , radiotherapy , 
curettage and electrodesiccation , cryosurgery, photodynamic therapy , MOHs surgery  and 
surgical excision depending on multiple factors such as sub -type of the BCC , risk status, lesion 
size,  anatomic location , patient age, etc . The currently recommended treat ments of 
electrodessication and curettage , surgical excision /MOHs surgery  or other modalities are often  
dependent upon the technique of the health care professional for adequate results  and often  
leave scars and require down time for healing .3   
 
1.3 Non -Surgical Approach  
 
Topi[INVESTIGATOR_746056] 5% Cream  
Topi[INVESTIGATOR_2855] 5% Imiquimod Cream is indicated for use on primary s uperficial BCC lesions. It require s 
doses 5 times per week for 6 weeks  and is applied by [CONTACT_102] . Imiquimod is a toll -like receptor 
(TLR) -[ADDRESS_1020325] via modification of the immune 
response and stimulation of apoptosis in BCC cells.4 Intense local inflammatory reactions can 
occur with side effects including  itching,  pain and tenderness at the target site,  burning, 
erythema,  scabbing, excoriation/flaking, induration,  edema, ulceration and vesicles.5 The 
cosmetic outcome for topi[INVESTIGATOR_746057]. 5% Imiquimod cream may also be used as pretreatment to Mohs in order to decrease tumor 
size and furthermore reduce surgical defect size  or as an adjuvant therapy .[ADDRESS_1020326] common 
skin effects include erythema, pruritus, dermatitis, burning sensation and photosensitivity.7 
 
Oral Medications/Systemic Therapi[INVESTIGATOR_746058] , such as  vismodegib and sonidegib , are used 
for locally advanced BCCs  in which curative  radiotherapy and surgery are not feasible . 
Vismodegib  is FDA approved for treatment in  adults with metastatic BCC or locally advanced BCC 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020327] common  AEs 
seen included muscle spasms, alopecia, nausea, weight loss and fatigue .2 
 
Intralesional Interferon   
Intralesional injection of interferon alpha -2b can be effective in treating low risk BCC lesions but 
it does not offer much patient convenience as it requires injections 3 times a week for 3 weeks  
and can be expensive . Side effects include erythema and flu -like symptoms.1,8 
 
Physical  Destruction  
Radiotherapy  (RT)/Radiation Therapy  
Radiotherapy, along with surgical excision  and Mohs surgery  have the lowest failure rates among 
treatment options for BCC with overall 5-year cure rates ranging from 79% -100%.[ADDRESS_1020328] concluded  cosmetic outcomes to be satisfactory where evaluated. A visible scar is common 
based on the dose regimen. Other  cosmesis related effects include alopecia, pi[INVESTIGATOR_91816], telangiectasia, fibrosis/scar, atrophy , contraction and epi[INVESTIGATOR_119230]; and rarely soft tissue 
necrosis, bone necrosis, cataracts , dry eye, conjunctival scarring,  and eyelid deformity in 
published studies.[ADDRESS_1020329] cooling applied to the BCC lesion disrupt s the cel lular architecture, 
membrane integrity, and enzymatic activity . Malignant cells are particularly sensitive to cryo 
therapy due to their nature of high -water content, high metabolism and microcirculation .7 Once 
the growth freezes, it tends to fall off within days. Treatment results may vary with this 
procedure; past research has shown that pi[INVESTIGATOR_746059], as well as erythema, edema, blistering , hypertrophic scarring, alopecia, tissue 
distortion and milia or pyogenic granuloma formation . 7 The cosmetic outcome is lower for 
cryotherapy compared to other treatment modalities. The pi[INVESTIGATOR_746060]’s Fitz patrick Scale ranking.  
 
Laser s & Photodynamic Therapy  (PDT)  
Photodynamic thera py is a light emitting therapy where  low risk BCC  lesions are treated with 
combined use of visible light and a photosensitizing agent, commonly  5-aminolevulinic acid 
(ALA) , methyl aminolevulinate (MAL)  or porfimer sodium . The skin is pre -treated using a 
photosensitizing, prescription gel that reacts with the light source, either IPL  (Intense pulsed 
light)  or a [ADDRESS_1020330] 
practice with this treatment method.7  This meth od has greater cosmesis when compared to 
surgical excision , with effects seen includ ing ulcerations  but is reserved for superficial BCC lesions 
less than 1 -2mm thick due to insufficient penetration of the photosensitizer and light source . 7 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020331] -treatment may be dependent on Fitzpatrick Scale 
ratings.  
 
Curettage and Electro desiccation (C&E)  
This treatment modality is a recommended treatment option for low -risk basal cell carcinomas 
in non -hair-bearing areas  that do not involve tissue past the subcutaneous layer . [ADDRESS_1020332] -inflammatory hyperpi[INVESTIGATOR_746061], there is no guarantee that another lesion will 
not develop nearby. Risk factors include reopening of wounds, scarring, temporary or permanent 
nerve damage (in regions w ith extensive nerves), subcutaneous bleeding and/or infections.  
 
1.[ADDRESS_1020333] -NPS treatment  (Visit 6). It involves a standard excision with [ADDRESS_1020334] -operative margin assessment with  second intention healing, linear repair or skin graft.2 
This treatment modality often leaves a scar and some areas are difficult to excise rendering this 
method infeasible.  
Mohs Micrographic Surgery  (MMS)  
Mohs Micrographic Surgery with margin assessment  is also a standard of care and has the lowest 
5-year recurrence rate (1% and 6% of primary and recurrent BCC lesions, respectively). It allows 
intraoperative analysis of 100% of the excision margin. 1 
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 8 of 37  
1.5 Alternative Approach  
CellFX ® System  
The CellFX Syste m is intended to be used for dermatological procedures in adult patients (greater 
than or equal to 22 years old) for the reduction, removal, and/or clearance of cellular -based 
benign lesions and low -risk basal cell carcinoma (BCC) , as an alternative to surgery and other 
more destructive methods for removing skin lesions. The CellFX System  utilizes localized delivery 
of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.  
The effect on tis sue takes place in a very shallow depth of skin directly below the sterile 
treatment tip. Histology of skin treated with CellFX has demonstrated selective effects on  cellular 
structures, including melanocytes, epi[INVESTIGATOR_73915] , and adnexal structures, inclu ding  sebaceous 
glands  and eccrine glands , with no apparent damage to the adjacent acellular dermis.  The device 
delivers less energy to tissue, and does not emit thermal energy like  laser, electro -surgery , or 
electro -cautery equipment.  
 
Prior Clinical Stud ies Summary  
Thirteen  (13) clinical studies have been or are currently being conducted using IRB approved non -
significant risk protocols and consent with  the Nano -Pulse Stimulation  (NPS) device . Two  
approved IDE pi[INVESTIGATOR_746062]. A combined total of approximately 
3,[ADDRESS_1020335] been delivered to  about 700  adult Subjects. Anatomic 
locations where NPS has been used include the face,  trunk , neck,  arms, legs, hands, and feet. 
Discomfort in all protocols was managed with localized injected buffered Lidocaine , often with  
epi[INVESTIGATOR_238] . Side effects consisted of relatively minor reactions consistent with routine wound 
healing. No device or procedure complications and no seriou s related adverse events were  
reported.  Only minor expected adverse skin effects  were observed that are expected to resolv e. 
 
A Non -Significant Risk ( NSR) Acne Feasibility study (NP -AF-009) was conducted using the Nano -
Pulse Stimulation (NPS) device on bac k acne . The study  involved the treatment of  acne lesions in  
a 7cmx7cm area of the back with 49 cycles of energy delivered via the 10.0mm x 10.0mm 
treatment tip across  a range of energy settings. The entire treatment area healed as expected 
with some residu al hyperpi[INVESTIGATOR_371], which is expected to resolve over time.  
 
An initial NSR BCC feasibility  study (NP -BC-005) demonstrated that the NPS Device  was successful 
in treating basal cell carcinoma lesions without safety concerns. A portion of [ADDRESS_1020336] data on the  safety 
and effectiveness of the CellFX System  for the treatment of  low-risk BCC lesions in  adult subjects . 
The data derived from this feasibility study will additionally be utilized to  determine  an optimal 
treatment  for basal cell carcinoma and  design a pi[INVESTIGATOR_746063].  
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 9 of 37  
2.0 STUDY DEVICE DESCRIPTION  
The study device being evaluated is the Pulse Bioscience CellFX® System . 
 
2.1 Pulse Bioscience  CellFX® System  
The CellFX  System  is manufactured by [CONTACT_746078], Inc. and  consists of an electrical pulse 
console (similar to  devices used to electro -coagulate tissue) combined with a handpi[INVESTIGATOR_746064]. The handpi[INVESTIGATOR_746065] 
a sterile, single patient -use treatment tip.  
Once the electrical pulse console is turned on and a  predetermined  treatment energy  setting is 
selected, a sequence of pre -programmed electrical pulses is administ ered to an area of skin 
directly beneath the treatment tip.  A common commercially available sterile contact  [CONTACT_746079]. The 
three system components are as follows , shown in Figure s 1-3.  
1. CellFX  Console including a built -in touch screen for setting selection . 
2. CellFX Handpi[INVESTIGATOR_13959]  (re-usable)  
3. Sterile Single Patient -Use CellFX Tip (multiple different tip sizes available)  
 
Figure 1 : CellFX Console  
 
Touchscreen Display
Accessories Drawer
Standby [CONTACT_746080][INVESTIGATOR_746066]-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 10 of 37  
            
                        
 
 Figure 2 : CellFX Handpi[INVESTIGATOR_746067] 3 : CellFX Tip s 
 
2.2 Proposed Indication for Use  
The Pulse Bioscience s’ CellFX System is investigational in the U.S. and the system is indicated for 
dermatologic procedures requiring ablation and resurfacing of the skin including the treatment  
of benign  and non -malignant lesions . 
 
 
3.0 PROTOCOL  
3.1 Study Objectives  
The primary objective s of this study are to evaluate the safety and effectiveness of the CellFX 
System in adults with low -risk basal cell carcinoma. Table 1 below reflects the study endpoints 
associated with the two objectives.  
 
 
 
 
 
 
 
 
 
 
 
LED Indic ator
Side Button –
Treatmen t Level 
Selection
10 Ft. CableTip R ecep tacle
Hook – For Hanging Handpi[INVESTIGATOR_746068] – Cycle Start
Console Connect or
7.5mm x 7.5mm Tips  10.0 mm x 10.0 mm 
Tips 5.0mm x 5.0mm Tips  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 11 of 37  
Table 1. Study Objectives and Endpoints  
 
Objectives  Endpoints  
Safety  
To evaluate the safety of the 
CellFX System in adults with 
low-risk basal cell carcinoma  Primary:  
• No serious  adverse events related to CellFX Treatment or Procedure  
Secondary:  
• Local Skin Reactions  (Investigator)  
• Procedural pain assessment (Subject)  
Effectiveness  
To evaluate the effectiveness of 
the CellFX System in adults with 
low-risk basal cell carcinoma  Primary:   
• Complete histological clearance of the target lesion on microscopic 
evaluation of hematoxylin and eosin stains  
Secondary:   
• Visible/clinical clearance of the target lesion by 
[CONTACT_2085]/dermatoscopic evaluation  
• Partial response  of the study lesion as assessed by [CONTACT_746077]  
(≥ 50% decrease in the product of the longest perpendicular  
diameter s of each  target lesion ) 
• SCAR -Q Appearance Scale (Subject)  
• Manchester Scar Scale (Investigator)  
• Healing assessment questions (Investigator)  
 
 
3.[ADDRESS_1020337] of a single treatment session with the CellFX System 
followed by [CONTACT_746081] r excision (with 5  mm margins) [ADDRESS_1020338] -treatment.   
Eligible subjects with 1-2 histologically  confirmed , primary  BCC lesion (s) who meet  the inclusion 
and exclusion criteria will be enrolled. The BCC lesion (s) may be present anywhere on the body 
except  neck, axilla, hands, feet, or genitals . In cases where the subject has more than 1-[ADDRESS_1020339] the lesion(s) to include in the study.  
The subject will receive treatment of their confirmed BCC lesion (s) with the CellFX system. The 
treatment area will be evaluated at [ADDRESS_1020340] -excision at 
14 days (suture removal) , 30 days  and 60 days  (typi[INVESTIGATOR_746069] -surgical excision) for a 
total of [ADDRESS_1020341] who has extensive experience in 
interpreting cutaneous neoplasms.  Details of the preparation, shipment and analysis of the 
excised tissue are provided in the Tissue Handling  and Analysis  Procedure.  
Photography of the study lesion(s) will be captured along with the investigator ’s assessme nts at 
all in-office visits. Detailed instructions for photography of the lesion area are provided in the 
photography instruction manual.  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 12 of 37  
 
3.3 CellFX Procedure  
The intended CellFX treatment device is described as the CellFX ® System using the skin contact[CONTACT_648982] “tip” . The three available tip  sizes  for this study are the 5.0mm x 
5.0mm, 7.5mm x 7.5mm, and 10. 0mm x 10.0mm  tips defined in  length and width , which  may 
range from 2.0mm to 3.0mm in depth. When a treatment tip is attached, the CellFX Handpi[INVESTIGATOR_746070] a timed series of energy pulses , referred to as a “Cycle”. The subject will be treated with 
appropriate tip size s according to the  size of the  BCC lesion .  The tip depth will be selected 
according to  the guidelines defined in  Table 2a  below. The BCC lesion(s) will be  treated with a 
pre-determined  treatment energy level  per tip size within the range  provided  in Table 2b.   
Table 2 a: Treatment Tip Depth Selection Guidance  
Tip Depth  
(mm)  Criteria   
2.[ADDRESS_1020342] r ecommended treatment depth tip  
 
3.0 Lesions with BCC located in the deeper dermis in the diagnostic biopsy sample.  
 
Diagnosed nodular/non -superficial BCC lesion located on the back or shoulder 
where skin is thicker and where the 2mm depth tip may not be sufficient.  
 
Table 2 b: Treatment Level Range per Tip  
Tip 
Size 
(L x W, mm)  Minimum  
Treatment Level 
per Cycle  
 (mJ/mm3)  Max imum  
Treatment Level 
per Cycle  
(mJ/mm3) 
5.0 x 5.0  45 155 
7.5 x 7.5 40 85 
10.0 x 10.0 20 85 
 
For this device, the term treatment level  (TL) refers to the energy density value (mJ/mm3) 
delivered to the tissue by [CONTACT_746082].  These  treatment  levels  do not exceed the 
maximum safe ranges of settings previously tested in clinical studies . Multiple cycles of energy 
may be delivered with one or more tip sizes  in order to treat the entire BCC lesion (s) along with 
a defined 5 mm margin  during  a single Cell FX treatment session.  
 
A tattoo will be applied prior to the CellFX  treatment to identify the treatment area  for 
evaluation . Four  tattoo marks  will be placed to identify  the margin of the treatment zone within 
the tissue area of the eventual ellipse of the excision.  The tattoo may be “touched up” or re -
applied at future visits as needed.  The tattoo will be applied to the area of the skin designated 
to be removed during th e surgical excision of the BCC lesion on Day 60 (Visit 6). An analgesic will 
be used to manage potential treatment discomfort during the CellFX treatment.  
                                                 
3.[ADDRESS_1020343] , and sufficient resources to 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020344] communication by [CONTACT_1755]/or his/her 
designated staff , advertisement and/or office ads . The Informed Consent discussion and 
signature [CONTACT_649001] [CONTACT_1755]/or designated staff. No study -
specific assessments will be performed prior to obtaining consent.  
 
A Screen Failure will be defined as a subject who did not meet one or more of the following 
criteria:  
• Did not meet all inclusion and/or exclusion criteria  
• Did not sign informed consent  
• Signed the informed consent but d id not subsequently undergo a treatment with the 
CellFX syste m 
 
A screen failure will not be ass igned a subject ID and information on this subject will not be 
entered in the electronic database. Information will be transcribed on the enrollment/screen  
failure log.    
 
4.[ADDRESS_1020345] meet ALL the following criteria:  
1. Subject is at least [ADDRESS_1020346] has 1-2 primary, non -recurrent, superficial, or nodular visible basal cell 
carcinoma  lesion  up to  1.5 cm in size with well -defined borders that has been 
verified by [CONTACT_9256].  
3. Lesion (s) is appropriate for full linear excision with [ADDRESS_1020347] is capable of giving signed informed consent , which includes compliance 
with the requirements and restrictions listed in the ICF and in this protocol.  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020348] BCC lesion (s) treated in a single treatment session  and must 
comply with all study procedures including follow -up visits.  
7. Subject consent s to have photographs taken of the BCC lesion(s) . 
8. Subject agrees to refrain from using all other lesion removal products or treatments 
(topi[INVESTIGATOR_746071] -the-counter medications  or treatments from PI [INVESTIGATOR_746072] ) during the study period.  
9. Subject agrees to refrain from prolonged sun exposure of the treatment area during 
the study period.  
 
4.2.2 Exclusion Criteria  
Candidates will be excluded from the study if ANY of the following apply:  
1. Subject has an implantable electronic medical device  (i.e., pacemaker, implantable 
cardioverter defibrillator) . 
2. Subject has an active infection or history of infection in designated test area within 
four weeks  prior to treatment.  
3. Subject is not willing or able to sign the Informed Consent.  
4. Subject is known to be immune compromised /has a history of immunosuppression 
(e.g., organ transplant, long -term use of psoralen) or genetic disease  (e.g., nevoid 
basal cell carcinoma syndrome [Gorlin syndrome], xeroderma pi[INVESTIGATOR_96223]) . 
5. The basal cell carcinoma lesion intended for treatment with the CellFX System is on 
the face, neck, scalp, axilla, hands, feet, or genitals.  
6. The basal cell carcinoma intended for treatment with the CellFX System  is a high -risk 
BCC subtype including perineurial, infiltrative, sclerosing , morpheaform , 
desmoplastic , micronodular, basosquamous  or exhibiting aggressive growth 
patterns.  
7. Subject is known t o be a keloid producer.  
8. Subject has allergies to Lidocaine or Lidocaine -like products.  
9. Subject has a history of radiation to the area intended for treatment . 
10. Subject has  current or prior metastatic BCC . 
11. Subject is  currently being treated or has been previously treated with Sonidegib or 
Vismodegib . 
12. Subject has r ecurrent BCC lesions .  
13. Subject has a  systemic infection . 
14. Subject has a  history of epi[INVESTIGATOR_002] .  
15. Subject has a  history of cardiac arrhythmia, myocardial infarction or structural heart 
disease .  
16. Subject is employed by [CONTACT_456], clinic site, or entity associated with the conduct 
of the study.  
17. Subject has  any condition or situation which, in the Investigator’s opi [INVESTIGATOR_1649], puts the 
subject at significant risk, could confound the study results, or may interfere 
significantly with the subject’s participation in the study.  
18. Subject has  a history of u se of any other investigational drug, therapy, or device 
within the past 30 days of enrollment or concurrent participation in another research 
study , with the exception of participation in a COVID vaccination related clinical trial . 
 
4.3 Process for Obtaining Informed Consent  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020349] sign and date the 
site’s current and approved Institutional Review Board (IRB) informed consent from to be eligible 
for study participation. The informed consent must contain all elements required by 21 CFR Part 
50 and ISO 1415 5:2011/AC:2011 and comply with the ethical principles of the Declaration of 
Helsinki.  
 
4.3.1  Process for Obtaining Informed Consent  
The patients will be informed by [CONTACT_648983]’s designee that they are 
free to refuse participation in this r esearch study. If they elect to participate, it will be 
made clear that they may withdraw from the study at any time without prejudicing 
further care.  
 
The Investigator or the Investigator’s designee will inform patients that their medical 
records will be subject to review by [CONTACT_648984]. This 
information will be used during the analysis of the results of the clinical study, but the 
patients’ identities will be treated as confidential. Patients will be assigned a unique 
study subject code that will not reveal the patients’ identity, and this code will be used 
on all data and data collection forms during the study period.  The Investigator will 
explain the conditions of the study, giving the patient sufficient time to ask qu estions 
and to consider whether to participate. Eligible patients who agree to participate will be 
asked to sign and date an IRB approved informed consent. If the patient agrees, an IRB 
approved consent form will be provided to the patient for signature [CONTACT_1629] d date. One copy 
shall be returned to the Investigator and filed in the patient’s case history; the other copy 
is for the patient to keep.  
 
4.3.[ADDRESS_1020350]’s confirmed 
participation in the study. The revised information will be sent to the Investigator for 
approval by [CONTACT_1201]. After approval of the IRB, a copy of this information must be 
provided to  the participating subjects, and the informed consent process as described 
above needs to the repeated. Please follow the central IRB guidelines on the process of 
re-consenting subjects.  
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 16 of 37  
4.4 Schedule of Events and Evaluations  
Schedule of events and evaluations required for this stu dy are provided in  Table 3. 
 
Table 3. Schedule of Events  
Study Activity/  
Procedure  Visit 1  
Screening/  
Enrollment  
& Tx  Visits [ADDRESS_1020351] -Tx Visit 6  
Excision  
(60-days 
Post -Tx) Visit [ADDRESS_1020352]  
Excision  
Study Day  0 3/7/14  30 60 74 90 120 
Visit Window  Day 0  ±2 days  ±5 days  ±5 days  ±3 days  ±5 days  ±5 days  
Type of Visit  
OV – In-Office  Visit Required  
OV/TM  – In-Office Visit or      
                 Telemedicine Visit   OV Visit 2 &  3: 
OV/TM  
 
Visit 4: OV OV/TM  OV OV OV/TM  OV 
Inclusion/Exclusion   
Informed Consent            
Demographics, Medical HX, 
Fitzpatrick Skin Type , etc.           
Lesion History            
History of Pi[INVESTIGATOR_746073]     a    *    *    a    a    *     
Lesion Assessment 
(Investigator)     a    *    *    a        *     
Tattoo Treatment Area           
CellFX Treatment            
Procedural Pain Assessment 
(Subject )              
Surgical Excision            
Suture Removal  (as 
applicable)            
SCAR -Q Appearance Scale 
(Subject )       b       
Manchester Scar Scale 
(Investigator)        b       
Healing Assessment 
Questions (Investigator)        b       
Lesion Measurement           b    
Clinical Clearance 
Assessment        b    
Adverse Events                              
Study Exit            
a Pre- and post -procedure / Surgical Excision  / Suture Removal  
b Pre-procedure / Surgical Excision   
* Required for in -office visits only  
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 17 of 37  
4.5 Screening / Enrollment  Procedures  (Visit 1)  
The following activities  are required at the time of the subject screening/ enrollment  visit.  The 
order of the activities may vary within reason as long as all activities are performed after 
consent is obtained.  The Screening Visit and  Treatment Visit (subject enrollment visit) may 
occur on different days.  
4.5.1 Activities prior to or on same day as stu dy enrollment  
• Evaluation for Inclusion/Exclusion criteria.  
• Collect Demographic information and medical history including but not limited to 
age,  gender , race, ethnicity, dermatologic conditions, and  Fitzpatrick skin type.                      
• Sign the cons ent form prior to any study activities.   
• Receive a copy of the signed consent form.  
 
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria.  Procedures conducted as part of the participant’s 
routine clinical management and obtained before signing of the ICF may be utilized for 
screening or baseline purposes provided the procedures met the protocol -specified 
criteria . 
4.5.[ADDRESS_1020353] will be assigned a unique Study 
Identification Number.   
4.5.3 CellFX Treatment Procedure  
• 1-2 clinically diagnosed BCC lesion (s) that meet the study criteria will be selected by 
[CONTACT_12707] . The identified lesion (s) will be labeled.  
• Baseline photographs  will be taken  (prior to use of analgesic for pain  management  
and prior to tattooing ). 
• Baseline c linical measurements of the BCC lesion(s) shall be taken  
• The site investigator  will perform a baseline lesion(s) assessment.   
• A template will be applied to the skin and used to map out the treatment application.  
• A tattoo (4 marks ) will be applied within the area d esignated for excision to mark the 
treatment zones for the purpose of identifying the treatment area during evaluation.  
• An analgesic for pain manag ement , such as local injection of lidocaine,  will be 
administered  to the selected study lesion  area(s) .  
• Each  study  lesion will be treated  with the CellFX system  per Table 2 according to the 
treatment tips utilized.  
• The total number of treatment cycles with the CellFX system will be recorded.   
• The subject will be asked to rate his/her pain immediat ely after  the treatment 
session  for each lesion treated with  the CellFX system by [CONTACT_2329] a numerical rating 
score , depi[INVESTIGATOR_6517] 4 . 
• Post -procedure lesion assessment will be performed by [CONTACT_093] . 
• Post -procedure p hotographic images of each selected lesion will be taken.  
• A light bandage and/or any physician  recommended dressing may be applied  before 
the subject leaves.  
• Any adverse events will be identified and documented.  
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 18 of 37  
4.6 3-Day Follow -up Visit (Visit 2)  
• This visit may be performed  in-office or as a telemedicine  visit. 
• Photographic images of each study lesion will be taken. Photographs are not required  if the 
visit is not performed in -office.  
• All lesions will be  examined and  clinically assessed by [CONTACT_6962]. If the visit is not 
performed in -office, clinical assessment is not required.  
• A light bandage and/or any physician recommended dressing may be applied post -
evaluation . 
• Any adverse events will be identified and documented. If the visit is not performed in office, 
the clinical site must inquire regarding any adverse events either by [CONTACT_25600], text, e -mail 
or video conference.  
 
4.7 7-Day Follow -up Visit (Visit 3)  
• This visit may be performed  in-office or  as a telemedicine  visit. 
• Photographic images of each study lesion will be taken. Photographs are not required  if the 
visit is not performed in -office.  
• All lesions will be  examined and  clinically assessed by [CONTACT_6962]. If the visit is not 
performed in -office, clinical assessment is not required.  
• A light bandage and/or any physician recommended dressing may be applied post -
evaluation.  
• Any adverse events will be identified and documented. If the visit is not performed in office, 
the clinical site must inquire regarding a ny adverse events either by [CONTACT_25600], text, e -mail 
or video conference . 
 
4.8 14-Day Follow -up Visit (Visit 4)  
• Photographic images of each  study lesion will be taken.  
• All lesions will be clinically assessed by [CONTACT_093].  
• A light bandage and/or any ph ysician recommended dressing may be applied post -
evaluation.  
• Any adverse events will be identified and documented.  
 
4.9 30-Day Follow -up Visit (Visit 5)  
• This visit may be performed  in-office or  as a telemedicine  visit. 
• Photographic images of each study lesion will be taken. Photographs are not required  if 
the visit is not performed in -office.  
• All lesions will be  examined and  clinically assessed by [CONTACT_6962]. If the visit is not 
performed in -office, clinical assessment is not required.  
• Any adverse events will be identified and documented. If the visit is not performed in 
office, the clinical site must inquire regarding any adverse events either by [CONTACT_25600], text, 
e-mail or video conference.  
 
4.10 60-Day Follow -up Visit ( BCC Surgical  Excision Day – Visit 6)  
• Photographic images of each study lesion will be taken.  
• All lesions will be clinically assessed by [CONTACT_093].  
• The site investigator shall assess each  treatment area based on the Manchester Sca r Scale 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 19 of 37  
prior to excision.  
• The site investigator shall complete the healing assessment questions  for each treatment 
area  prior to excision . 
• Clinical measurements of the BCC lesion(s) shall be taken  
• The site investigator shall complete the  clinical lesion clearance assessment for each 
treatment area prior to excision.  
• The subject shall assess each treatment area based on the SCAR -Q Appearance Scale prior 
to excision.  
• A complete surgical tumor excision will be performed by [CONTACT_093] w ith at least 5mm 
margins for each study lesion.  
• The subject will be asked to rate his/her pain immediately after surgical excision by [CONTACT_2329] a 
numerical rating score.  
• All tissue shall be handled and shipped to the dermatopathology laboratory per the Tissue 
Handling  and Analysis  Procedure.  
• Any adverse events will be identified and documented.  
 
4.[ADDRESS_1020354] -Excision  Follow -up Visit (Visit 7) 
• Photographic images of each study area will be taken . 
• Each  study area  will be clinically assessed by [CONTACT_093].  
• Sutures shall be removed , as applicable . 
• Photographic images of each study area will be taken post -suture removal.  
• Any adverse events will be identified and documented.  
 
4.[ADDRESS_1020355] -Excision Follow -up Vis it (Visit 8) 
• This visit may be performed in -office or may be performed as a  telemedicine  visit.  
• Photographic images of each study area  will be taken. Photographs are not required  if the 
visit is not performed in -office.  
• Each  study area  will be  examined and  clinically assessed by [CONTACT_6962]. If the visit 
is not performed in -office, clinical assessment is not required.  
• Any adverse events will be identified and documented. If the visit is not performed in office, 
the clinical site must  inquire regarding any adverse events either by [CONTACT_25600], text, e -mail 
or video conference.  
 
4.[ADDRESS_1020356] -Excision Follow -up Visit (Visit 9)  
• Photographic images of each study area will be taken .  
• Each  study area  will be clinically assessed by [CONTACT_6962].  
• The site investigator shall assess each treatment area based on the Manchester Scar Scale.  
• The site investigator shall complete the healing assessment questions  for each treatment 
area.  
• The subject sh all assess each treatment area based on the SCAR -Q Appearance Scale.  
• Any adverse events will be identified and documented.  
 
 
4.[ADDRESS_1020357] Withdrawal  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020358] of medical care and will n ot be replaced.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records.  
 
4.[ADDRESS_1020359] be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_746083] t he missed visit as soon as 
possible , counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or will continue in the 
study.  
• For  the surgical excision visit (Visit 6), the sites must confirm the surgical excision date with 
the participant [ADDRESS_1020360] does not confirm and/or does not come in on their schedule excision 
date, the site must attempt to contact [CONTACT_746084]. If the 
site cannot reach the participant, the site is to send a certified letter to the participant’s last 
known mailing address or local equivalent methods . 
• Before a participant is deemed lost to follow up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3  telephone calls and , if 
necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_746085]’s 
medical record.  
• If the participant continues to be unreachable, he/she will be  considered to have withdrawn 
from the study.  
5.0 BENEFITS AND RISKS  
5.1 Benefits  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020361] of warning s, precautions , and potential adverse events, please refer to the 
Instructions for Use (IFU) for the Pulse Bioscience CellFX® System.  
An additional risk for study participants is the delay in performing surgical excision of the tumor; 
however, basal cell c arcinomas are slow -growing, so a dela y of [ADDRESS_1020362] of care for basal cell carcinoma 
and will also be occurring in this study, risks of these procedures are not considered in the 
benefit/risk assessment.  
 
5.[ADDRESS_1020363] will receive full care 
of their B CC lesion(s).  
All efforts will be made to minimize these risks by:  
• Site Selection  
• Patient Population that represents  the demographics of the U.S  
• Ensuring compliance to the protocol and IFU  
• Study monitoring  
• Safety processes -protocol adverse events reporting requirements  
 
The following plan is set in place in order to mitigate the risk of the study participant treated with 
the CellFX system not returning for their surgical excision visit to receive full care of their BCC 
lesion(s):  
• Prominent language is added to the Informed Consent Form to emphasize that the CellFX 
treatment has not yet been shown to remove all cells from a skin tumor, and therefore 
surgical removal is of the utmost importance to ensure that the cancer does not return or 
spread.  
• Training of the PI [INVESTIGATOR_746074], an explanation of the 
importance for all subjects to compl ete their surgical excision of the diagnosed BCC lesion, 
training to remind and confirm the study visits with the subjects at each visit, with emphasis 
on the surgical excision visit.  
• Subject compensation is structure d to motivate the subject to complete the surgical 
excision, and safety follow up visits with the highest compensation assigned to the surgical 
excision visit (Visit 6), higher monetary values assigned to the later follow -up visits (visits 7 -
9), as well as a n all-visit bonus offered for subjects who complete all study visits . 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 22 of 37  
• Site compensation includes an all -visit bonus to motivate the site to closely follow -up with 
the study subjects to ensure all visits are completed . 
• Remote and on -site monitoring of subje ct visits at all participating sites to ensure 
compliance of subject attending scheduled study visits.  
 
 
6.[ADDRESS_1020364] deviation , median, 
minimum and maximum.  No inferential tests are planned for this study, but 2 -sided confidence 
intervals will be produced where appropriate. Where 2 -sided p -values are calculated, they 
should be interpreted as descriptive only.  
 
6.2 Analysis of the Primary Effectiveness Endpoint  
The count and proportion with the primary endpoint of histological clearance will be calculat ed 
along with a 95% confidence interval  (CI). The primary population for this analysis will be the 
Per-Protocol population, though estimates will be produced for the modified intent -to-treat / 
safety population  (patients who begin treatment)  and Complete T reatment population 
(subjects who complete all required cycles of treatment).   
 
6.3 Analysis of Secondary Endpoints  
No formal hypothesis testing is planned for secondary endpoints. Any p -values comparing 
groups should be considered descriptive. The secondary e ndpoints will be evaluated using the 
modified intent -to-treat / safety  population, but these analyses may be repeated for  complete  
treatment and per-protocol populations as well.  
 
6.3.1 Change in Lesion Size  
Lesion size (as measured by [CONTACT_746086] ) will  be 
calculated at baseline and at follow -up day  [ADDRESS_1020365] 
diameters (longest length and  longest perpendicular  width) of each study lesion will be 
measured and the product will be calcul ated  for each individual study lesion at baseline 
and at [ADDRESS_1020366] adhesive 
ruler will also be included in photo graphs taken of each study lesion. Within -lesion 
change in lesion size from baseline to the 60 -Day follow -up time -point will be calculated. 
A mixed model for repeated measures will be used to estimate the mean reduction and 
its 95% confidence interval. Baseline lesion size will be included as a fixed effect.  
 
6.3.2 Lesion Reduction Category  
The visible/clinical clearance of the target lesions will be rated according to the lesion 
reduction categories listed in Table 4. The l esion reduction category will be derived from 
the lesion size measurements at baseline and follow -up day  [ADDRESS_1020367] -NPS treatment  
described in Section 6.3.1 . The % redu ction will be calculated as the change in lesion size 
divided by [CONTACT_208255]. This percentage will be categorized according to the table  
4 below:  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 23 of 37  
 
 
 
 
Table 4. BCC Lesion Reduction Categories  
 
BCC Lesion Reduction Categories  
CLEAR  
0mm/100% reduction  MOSTLY CLEAR  
99-51% reduction  PARTIALLY CLEAR  
50-25% reduction  NOT CLEAR  
<25% reduction  
 
 
6.3.3 Partial response  of target (study) lesion  as assessed by [CONTACT_746087]. Partial response is defined as a  
≥ 50% decrease in the product of  the perpendicular  diameter s of each  target /study BCC lesion 
compared to baseline.  The 50% reduction  will be determined through  the product  of the 
long est perpendicular bidimensional diameter s (longest length and longest perpendicular 
width) of each study lesion treated.  Calipers will be provided to each study site to perform 
the measurements per standa rdized procedures. A standard adhesive ruler will also be 
included in photographs taken of each study lesion. Partial response will be assessed for in -
clinic measurements at follow -up day  [ADDRESS_1020368]-NPS treatment . The number and proportion 
of lesions meeting the definition of partial response and confidence interval for the 
proportion will be calculated . 
 
6.3.4 SCAR -Q Appearance Scale (Subject)  
The SCAR -Q is a patient -reported outcome  instrument designed to  measure outcomes 
specific to any type of scar .  This instrument has subscales for scar appearance , psychosocial 
impact  and scar  symptoms . Least -square means and confidence intervals will be calculated 
for each scale and subscale using  generalized linear models with lesion size included as  a 
fixed effec t.  
 
6.3.5 Manchester Scar Scale (Investigator)  
The Manchester Scar Scale  evaluates the following five characteristics  of scar: color (score: 
1–4), distortion (score:  1–4), contour (score: 1 –4), texture (score:  1–4), and transparency 
(score: 1 –2). The distributi on of responses will be summarized for each characteristic. Least -
square means and confidence intervals will be calculated for the total score using generalized 
linear models with treatment lesion size included as  a fixed effect.  
 
 
6.3.6 Healing assessment ques tions (Investigator)  
The following assessment questions will be asked on the Day [ADDRESS_1020369] -surgical excision  visit: 
a. Is the healing pattern cosmetically acceptable? (yes, no)  
b. How likely is a scar? (1 = unlikely, 2 = possible, 3 = probable)  
c. Once healed, how do you anticipate the treated area will look compared to curettage 
and desiccation? (1 = better, 2 = the same, 3 = worse)  
d. Once healed, how do you anticipate the treated  area will look compared to surgical 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 24 of 37  
excision? (1 = better, 2 = the same, 3 = worse)  
The distribution of responses will be summarized for each question.  
 
6.4 Safety Endpoints  
Unless otherwise noted, the safety population will be used to assess safety endpoints.  
6.4.1 Primary Safety Endpoint  
The primary safety endpoint is the incidence of any serious AEs or complications associated 
with the application of NPS (procedure and treatment). Information about AEs and 
complications will be solicited by [CONTACT_746088] -up visits.  The count 
and proportion with the primary  safety  endpoint  will be calculated along with a 95% 
confidence interval.  Adverse events and complications will also be summarized by [CONTACT_150016].  
 
6.4.2 Investigator Local Skin Reaction Assessment  
The Investigator  will perform  clinical assessments on the local skin reaction of the treatment 
area based on the following characteristics: presence and severity of erythema, edema, 
exudate, eschar, peeling scaling, bleeding,  ulceration, scarring,  and pi[INVESTIGATOR_9491]. 
Assessment will be based on a validated 5 -point scale: None, Mild, Moderate, Moderate to 
Severe, Severe. The wound healing characteristics will be assessed by [CONTACT_746089] 
14-Day and 60-Days Post -NPS visits . The [ADDRESS_1020370] -NPS visits are 
optional in -office and will be summarized separately and included as a descriptive analysis . 
The rate of each event individually and a composite of any of these events will be calculated 
for each treated lesion area.  The number and proportion of lesions with any reporting of any 
erythema, edema, exudate, eschar, peeling scaling, bleeding, ulceration, scarring,  or 
pi[INVESTIGATOR_9491] (regardless of severity) will be summarized by [CONTACT_5586] -point.   
 
6.4.3 Partic ipant Assessment of Procedural Pain  
The p articipant  will give an assessment of procedural pain on an 11 -point scale ranging from 
0 (no pain) to 10 (worst pain imaginable). The Pain Assessment Chart  with an assigned 
numerical rating between 0 (smiling) and 10 (crying) will be used to assess pain at Day 0, as 
reference in Figure 4. The pain scale will be asses sed immediately after each lesion treatment 
session .  
Pain levels will be grouped into four categories: No Pain (Score of 0), Mild Pain (Scores of 1 -
3), Moderate Pain (Scores of 4 -6) and Moderate -to-Severe Pain (Scores of 7 -10). The number 
and percent age will be tabulated for each category of pain, averaged for overall pain and 
may be analyzed against other parameters.  
 
 
   Figure 4: Pain Assessment Chart  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 25 of 37  
 
6.5 Sample Size Determination  
No formal hypothesis tests will be performed for this study, so the sample size was selected to 
produce a representative sample of BCC lesions to determine whether treatment effects are 
consistent  across study participants . A maximum of 30  participants will be treated to allow for 
assessment of the endpoints outlined in th is protocol.  
 
6.6 Populations for Analyses  
The following populations are defined in Table 5.  
 
Table 5. Population Descriptions for Analysis  
Population  Description  
Modified Intent -to-treat / 
Safety Population  All enrolled participants who began  treatment  with the CellFX system , 
irrespective of completed study treatment session, subsequent 
withdrawal, or deviation from the protocol .  
Complete Treatment  This population consists of m ITT participants who completed  the entire 
CellFX treatment session .  
Per-Protocol  Participants who received treatment, completed the CellFX treatment 
session, excision surgery and all required study visits . 
 
6.7 Sub-Group Analyses  
Subgroup analyses will be performed for the following subgroups:  
o Lesion Size Tertiles  
o Fitzpatrick skin type  
 
6.[ADDRESS_1020371] treatment 
results, and a tippi[INVESTIGATOR_007] -point analysis will be performed for the endpoints at 60 days to determine 
whether the missing data could change the inference compared to the primary models.  
6.10  Exploratory Analysis  

NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020372] -NPS.  
Exploratory analysis may be performed for d ermatologic similarities of skin type based on 
anatomic subcategories:  
▪ Sun-exposed limbs  
▪ Non -sun exposed limbs  
▪ Torso  
 
 
7.[ADDRESS_1020373] photographs will be reviewed 
(monitored) on an ongoing basis. Digital images will be transferred /stored  in a secure, password 
protected portal.  
 
 
8.0 ADVERSE EVENTS  
Pulse Biosciences will classify each reported Adverse Event according to ISO [ZIP_CODE]:2011. All protocol 
specific AEs, whether device -related or not, will be recorded on the AE case report form  and reported . 
Data to be collected will include the description o f the AE, onset , and resolution dates (or whether the 
AE is ongoing), severity, management/treatment, outcome, and determination of the relationship to the 
device and/or procedure. All AEs related to the lesion site(s)  should be reported and classified by [CONTACT_746090].   
All AE information will be collected from enrollment through  the last study visit at  60 days following the 
surgical excision of the BCC lesion(s) ( 120 Days after the  CellFX treatment session) . All AEs will be followed 
until the event has resolved (in the case of permanent impairment, the event will be followed until it 
stabilizes, and the ov erall clinical outcome has been ascertained). Medical occurrences that begin before 
receiving a CellFX treatment  but after obtaining informed consent will be recorded on the Medical 
History section of the CRF rather than the AE section.  
 
When reporting AEs /SAEs, the Investigator should include the following information:  
• Description of event  
• Onset of event  
• Duration of event (including resolution dates or whether the AE is ongoing)  
• Severity  
• Relationship to device  or procedure  
• Action taken  
• Subject  outcome  
 
Severity describes the intensity of an event and will be assessed as:  
• Mild : The AE does not interfere in a significant manner with the subject’s normal functioning 
level.  
• Moderate : The AE produces some impairment of function but not hazardous to health.  
• Severe : The AE produces significant impairment of function or incapacities and/or it is a hazard 
to the subject.  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 27 of 37  
 
Relationship to device or procedure will be assessed as:  
• Unlikely : There is no indication that the AE was caused by [CONTACT_746091].  
• Possibly : It cannot be excluded that the AE was caused by [CONTACT_746091].  
• Likely : A causal  relationship between the investigational  or standard of care  device and the AE 
is at least a reasonable possibility,  i.e. there is evidence or argument suggesting a causal 
relations hip.  
 
8.1 Adverse E vent Definitions  
8.1.1 Adverse Event (AE): ( ISO [ZIP_CODE]:2011 3.2 )  
Any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users , or other 
persons, whether or not related to the investigational medical device .  
NOTE 1: This definition includes events related to the investigational medical 
device .  
NOTE 2: This definition includes events related to the procedures involved.  
*For the p urposes of this protocol , only dermatologic AEs will be reported  to 
the Sponsor . 
 
8.1.[ADDRESS_1020374] (ADE): ( ISO [ZIP_CODE]:2011 3.1 )  
Adverse event related to the use of an investigational medical device  
NOTE 1: This definition includes adverse events resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or 
operation, or any malfunction of the investigational medical device.  
NOTE 2: This definition includes any event resulting from use error or from 
intentional misuse of the investigational medical device  
 
8.1.3 Serious Adverse Event (SAE) (ISO [ZIP_CODE]:2011 3.37)  
 Adverse event that  
a) led to  death,  
b) led to serious deterioration in the health of the subject, that either resulted 
in  
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, or  
3) in -patient or prolonged hospi[INVESTIGATOR_059], o r  
4) medical or surgical intervention to prevent life -threatening illness or 
injury or permanent impairment to a body structure or a body function,  
 c) led to fetal distress, fetal death or a congenital abnormality or birth defect.  
NOTE 1: Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure 
required by [CONTACT_10396], without serious deterioration in health, is not considered a 
serious adverse event.  
 
 
 
8.1.[ADDRESS_1020375] (SADE): (ISO [ZIP_CODE]:2011 3.36)  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020376] (UADE): (21CFR812.3)  
Any serious adverse effect on health or safety or any life -threatening problem 
or death caused by, or associated with, a device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of incidence in the 
investigatio nal plan or application, or any other unanticipated serious problem 
associated with a device that relates to the rights, safety, or welfare of subjects.  
 
8.2 Device Deficienc ies (ISO [ZIP_CODE]:2011 3.15 )  
8.2.[ADDRESS_1020377] to its identity, 
quality, durability, reliability, safety , or performance .  
 
NOTE : Device deficiencies include malfunctions, use errors, and inadequate labelling.  
 
Device Malfunction  is a failure of the study device to perform in accordance with its   
intended purpose when used in accordance with the instructions for use or study 
protocol.  
 
8.[ADDRESS_1020378] person for these reporting requirements .  
 
                             Table 6. Investigator Responsibilities for Submitting Adverse Event s to the Sponsor  
Type of Adverse Event  Reporting Timeframe  
*Serious Adverse Device Effects 
(SADE), including Unanticipated 
Serious Adverse Device Effect 
([LOCATION_003]DE)  As soon as possible, but in no case later than [ADDRESS_1020379] learns of the event or of new 
information in relation with an already reported event   
**Serious Adverse Events (SAE)  
 As soon as possible, but in no case later than [ADDRESS_1020380] learns of the event  or of new 
information in relation with an already reported event   
Adverse Device Effects (ADE)  
 As soon as possible, but in no case later tha n [ADDRESS_1020381] learns of the event  or of 
new information in relation with an already reported event  
All other AEs  
(dermatologic  only ) Submit in a timely manner after the clinical site first learns of 
the event   
**Device Deficiency with SADE 
potential  
 As soon as possible, but in no case later than [ADDRESS_1020382] learns of 
the deficiency  
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 29 of 37  
*The Sponsor will report the results of an evaluation of an unanticipated serious or serious adverse 
device effect to the FDA and all reviewing IRBs and investigators within [ADDRESS_1020383] per 21 CFR 812.150.  
 
**It is the responsibility of the investigator to inform their IRB of serious adverse events and device 
deficiencies as required by [CONTACT_648997].  
 
 
9.0 STUDY MANAGEMENT  (SPONSOR RESPONSIBILITIES)  
9.[ADDRESS_1020384] of the study and is conducted according to the 
Declaration of Helsinki, Protection of Human Volunteers (21 CFR 50), Institutional Review Boards 
(21 CFR 56), and Obligations of Clinical Investigators (21 CFR 312). The study sponsor will adhere 
to sponsor general duties as d escribed in ISO [ZIP_CODE]:2011, Clinical investigation of medical 
devices for human subjects – Good clinical practice, and CFR Part 812, 50, 56, [ADDRESS_1020385]  identification code (ID number). All study records will be kept in a locked , secure 
area and clinical information will not be released witho ut written permission of the subject, 
except as necessary for monitoring by [CONTACT_1622]. The Investigator must also comply with all 
applicable privacy regulations (e.g., Health Insurance Portability and Accountability Act of 1996).  
 
General Duties  
Pulse Biosci ences will ensure that the application is submitted to the appropriate regulatory 
authorities, obtaining copi[INVESTIGATOR_746075], ensuring proper clinical site monitoring, ensurin g patient informed 
consent is obtained, providing quality data that satisfies regulations and informing the 
Investigators and IRBs of unanticipated adverse device effects, events, and deviations from the 
protocol as appropriate.  
 
9.[ADDRESS_1020386] the study.  
 
9.3 Site Training  
The training of appropriate clinical site personnel will be the responsibility of the Sponsor. The 
Investigator is responsible for ensur ing that his/her staff conduct the study according to the 
protocol. To ensure proper device usage, uniform data collection, and protocol compliance, the 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020387] enrollment, the Sponsor will obtain the essential regulatory documents 
required to initiate the study.  The Sponsor will be responsible for the review and 
approval of the following essential documents:  
 
• Current Protocol  Revision  
• Investigator  Agreement  
• IRB approval letter for the protocol and consent  form  
• IRB approved consent  form  
• IRB membership roster or assurance number  
Copi[INVESTIGATOR_746076].  
 
9.5.2 Periodic Monitoring Visits  (Onsite and Remote)  
Periodic monitoring visits will be made at the investigational site throughout enrollment 
of the clinical study to assure that the Investigator obligations are fulfilled, and all 
applicable regulations and guidelines are being followed. These visits will assure that the 
facilities are still acceptable; the protocol and investigational plan are being followed, 
the IRB/HREC has been  notified of approved protocol changes as required, complete 
records are being maintained, appropriate and timely reports have been made to the 
Sponsor and the IRB, device and device inventory are controlled and the Investigator is 
carrying out all agreed activities. The monitor will verify accuracy of CRF or EDC 
completion against source documents maintained at the site.  
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 31 of 37  
During monitoring visits, the Monitor will perform a review of study eligibility, 
Inclusion/Exclusion criteria, informed consent, all re ports of device malfunction, all 
events meeting criteria for serious adverse event reporting as well as safety and efficacy 
endpoints.  
Additional review will be performed on a site -by-site basis, as warranted by [CONTACT_746092].  
The monitor will ensure that Investigators are aware of the regulatory requirement to 
maintain information in the study subject’s medical records which corroborate data 
collected on the CRF or EDC system.  To comply with these regulatory requirements, the 
following information will be maintained and made available as required by [CONTACT_131494]/or regulatory inspectors:  
The monitor will compare key variables (demographics, inclusion/exclusion criteria, and 
safety) on the CRFs or EDC database with each subje ct’s source documents. Any 
discrepancies will be noted and resolved.  
 
9.5.3 Site Close -out Visit  
Upon completion of the clinical study (when all subjects enrolled have completed the 
follow -up visits and the CRFs or EDC and queries have been completed), the Sponsor will 
notify the site  of closeout  and a study  closeout  visit will be performed.  All CRFs,  unused  
study  devices,  and any unused study materials will be collected and returned to the 
Sponsor. The Monitor will ensure that the Investigat or’s regulatory files are up to date 
and complete and that any outstanding issues from previous visits have been resolved. 
Other issues which will be reviewed at this visit include discussing retention of study 
files, possibility of site audits, publicatio n policy, and notifying the IRB of study closure.  
 
9.[ADDRESS_1020388] specific deviations will be 
reported to the sponsor in writing. Investigators will also adhere to procedures for reporting 
study deviations to their IRB in accordance with their specific IRB reporting policies and 
procedures.  
Good Clinic al Practice (GCP) regulations require that Investigators maintain accurate, complete , 
and current records, including documents showing the dates and reasons for each deviation from 
the protocol.  
 
9.[ADDRESS_1020389] been closed. All unused study materials and study devices will be collected and 
returned to P ulse Biosciences or appropriately discarded as per instruction. After study closure, 
a final report will be completed.  
 
9.8 Audits / Inspections  
Pulse Biosciences,  national/international regulatory authorities  and IRBs may conduct initiated 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020390] of this feasibility study.  
 
9.11 Case Report Forms /Transmission of Data  
All required data for this study will be collected via web -based electronic data capture (EDC) 
system and entered in electronic Case Report Forms (eCRFs).  A unique study identifier will be 
assigned to each study subject. The database will contain only the  study identifier to identify the 
subject.  
Required data will be recorded on the appropriate electronic Case Report Forms at the time of 
or as soon as possible after the subject visit. This will enable timely monitoring visits.  
Any data discrepancies identified during data review or a monitoring visit will be queried by [CONTACT_648999] a timely manner.  
 
9.[ADDRESS_1020391]. The Principal 
Investigator [INVESTIGATOR_354844] U.S. Food and Drug Administration or any other local governmental body to revie w the study 
subjects’ medical records including any test or laboratory data that might have been recorded 
on diagnostic tests media (e.g., photographs, etc.).  
 
 
 
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page [ADDRESS_1020392].  
Upon completion or termination of the study, the Investigator will submit a final written summary to 
the IRB. The summary should be submitted to the Sponsor within three (3) months of study completion 
or termination. The Investigator will provide the Sponsor with copi[INVESTIGATOR_28078]/HREC actions regarding 
the study.  
 
10.[ADDRESS_1020393] comply with the safety reporting requirements specified in Section 8.3. 
Qualified study staff at each clinical site will perform primary data collection drawn from source - 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 34 of 37  
document (hospi[INVESTIGATOR_433206]) reviews. The Monitor will perform clinical monitoring, 
including review of CRFs , source documents and/or Electronic Data Capture ( EDC) system  with 
verification of study eligibility, informed consent process, scheduled follow -up visits and AEs to 
the source documentation.  
 
10.3 Source Do cuments  / Records Retention  
The investigator shall maintain accurate, complete, and current records relating to the 
investigator's participation in an investigation including records of each subject's case history 
and exposure to the device. Case histories  include the case report forms and supporting data 
including, for example, signed and dated consent forms and medical records including, progress 
notes of the physician, the individual's hospi[INVESTIGATOR_648976](s), and the nurses' notes. Such 
records shal l include:  
 
1. Documents evidencing informed consent and, for any use of a device by [CONTACT_29751], any written concurrence of a licensed physician and a brief 
description of the circumstances justifying the failure to obtain informed consent. The case  
history  for each  subject  shall  document  that informed  consent  was obtained  prior to participation 
in the  study.  
 
2. All relevant observations, including records concerning adverse device effects (whether 
anticipated or unanticipated), information and data on the condition of each subject upon 
entering,  and during  the investigation,  including  information  about  relevant previous  medical  
history  and the results  of all diagnostic  tests.  
 
Investigator files containing all rec ords and reports of the investigation should be retained for a 
minimum of [ADDRESS_1020394] Pulse 
Biosciences before destroying any records and reports pertaining to the study to ensure they no 
longer need to be retained.  
 
10.4 Device Accountability  
The Investigator s hall maintain adequate records of the receipt and disposition of all study 
devices. When the enrollment is complete, the Investigator shall return any unused devices to 
the Sponsor . At the completion of the study, all devices shall be returned to the Sponsor . The 
Investigator’s copy of the Device Accountability Log must document devices that have been 
returned to the sponsor.  
 
The device accountability log will include records of receipt, use or disposition of a device that 
relate to:  
 
1. The type  and quantity  of the device,  the dates  of its receipt,  and the lot number.  
2. The names  of all persons  who  received,  used,  or disposed  of each  device.  
3. Why and how many device (s) were  returned to the Sponsor , or otherwise disposed  of. 
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 35 of 37  
 
11.0 REFERENCES  
1. Lomas A, Leonardi -Bee J, Bath -Hextall F. A systematic review of worldwide incidence of 
nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069 -1080.  
2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Basal cell 
skin cancer version 1. 2018.  
3. Migden MR, Chen L, Silapunt S, eds. Basal cell carcinoma. Advances in treatment and 
research. Switzerland: Springer Nature Switzerland AG, 2020.  
4. Oldfield, V., Keating, G.M. & Perry, C.M. Am J Clin Dermatol (2005) 6: 195. 
https://doi.org/10.2165/[ZIP_CODE] 071-200506030 -[ZIP_CODE]  
5. Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, Owens M. Imiquimod 5% cream for 
the treatment of superficial basal cell carcinoma: a double -blind, randomized, vehicle -
controlled study. J Am Acad Dermatol. 2002 Sep;47(3):390 -8. doi: 
10.1067/mjd.2002.126215. PMID: 12196749.  
6. Van der Geer S, Martens J, van Roij J, Brand E, Ostertag JU, Verhaegh ME, Neumann HA, 
Krekels GA. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular 
basal cell carcinoma in the face: a  prospective randomized controlled study. Br J Dermatol. 
2012 Jul;167(1):110 -5. doi: 10.1111/j.1365 -2133.2012.[ZIP_CODE].x. Epub 2012 May 21. PMID: 
22385074.  
7. Bahner JD, Bordeaux JS. Non -melanoma skin cancers: photodynamic therapy, cryotherapy, 
5-fluorouracil, i miquimod, diclofenac, or what? Facts and controversies. Clin Dermatol. 2013 
Nov-Dec;31(6):792 -8. doi: 10.1016/j.clindermatol.2013.08.020. PMID: 24160289.  
8. R. Cornell, et all. Intralesional interferon therapy for basal cell Carcinoma. AAD VOLUME 23, 
ISSUE 4 , P694 -700,  OCTOBER 01, 1990  
9. Cho M, Gordon L, Rembielak A , Woo TC. Utility of radiotherapy for treatment of basal cell 
carcinoma: a review. Br J Dermatol. 2014 Nov;171(5):968 -73. doi: 10.1111/bjd.[ZIP_CODE]. Epub 
[ADDRESS_1020395] 26. PMID: 25041560  
10. Megna M, Fabbrocini G, Marasca C, Monfrecola G. Photodynamic Therapy and Skin  
Appendage Disorders: A Review. Skin Appendage Disord. 2017;2(3 -4):[ADDRESS_1020396] of 595 nm 
pulsed dye laser on superficial and nodular basal cell carcinomas. 08 July 2009. 
https://doi.org/10.1002/lsm.[ZIP_CODE]  
12. Klassen AF, Ziolkowski N, Mundy LR, Miller HC, McIlvride A, DiLaura A, Fish J, Pusic AL. 
Development of a New Patient -reported Outcome Instrument to Evaluate Treatments for 
Scars: The SCAR -Q. Plast Reconstr Surg Glob Open. 2018 Apr 24;6(4):e1672. doi: 
10.1097/GOX.0000000000001672. PMID: 2987 6160; PMCID: PMC5977950 . 
13. Fearmonti R, Bond J, Erdmann D, Levinson H. A review of scar scales and scar measuring 
devices.  Eplasty. 2010;10:e43. 2010 Jun 21.  
 
12.0 APPEND ICES   
12.1 Appendix A: Patient Informed Consent  
12.2 Appendix B: Case Report Forms   
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 36 of 37  
APPENDIX A: Patient Informed Consent  
 
Patient Informed Consent will be provided as a separate attachment . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 37 of 37  
 
APPENDIX B: Case Report Forms  
 
Case Report Forms will be provided as a separate attachment . 
 